Rep. Julie Johnson Sells Off Shares of Eli Lilly and Company (NYSE:LLY)

Representative Julie Johnson (D-Texas) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on May 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on April 7th. The trade occurred in the Representative’s “MERRILL LYNCH LONG TERM GROWTH” account.

Representative Julie Johnson also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 4/30/2025.
• Sold $1,001 – $15,000 in shares of Blackstone (NYSE:BX) on 4/22/2025.
• Purchased $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 4/22/2025.
• Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 4/15/2025.
• Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 4/11/2025.
• Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 4/11/2025.
• Sold $1,001 – $15,000 in shares of DT Midstream (NYSE:DTM) on 4/7/2025.
• Sold $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 4/7/2025.
• Sold $1,001 – $15,000 in shares of Howmet Aerospace (NYSE:HWM) on 4/7/2025.
• Sold $1,001 – $15,000 in shares of Carlisle Companies (NYSE:CSL) on 4/7/2025.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $757.23 on Friday. The stock has a fifty day moving average price of $797.84 and a 200-day moving average price of $805.85. The company has a market cap of $717.65 billion, a price-to-earnings ratio of 64.67, a PEG ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Eli Lilly and Company’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.58 earnings per share. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. Eli Lilly and Company’s payout ratio is 48.82%.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently made changes to their positions in LLY. WestEnd Advisors LLC grew its stake in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $27,000. Citizens National Bank Trust Department grew its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $40,000. Finally, Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $43,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of several research analyst reports. HSBC lowered Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Truist Financial raised their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Guggenheim reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. UBS Group reduced their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Finally, Citigroup reduced their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,011.37.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.13% of the stock is currently owned by insiders.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.